Navigation Links
Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions
Date:4/7/2011

y lead to discontinuation of CUVPOSA™. CUVPOSA™ may present abdominal distention, pain, nausea, or vomiting. It is important for physicians to assess patients for constipation, particularly within four to five days of initial dosing or after a dose increase. Diarrhea associated with CUVPOSA™ may be an early symptom of incomplete mechanical intestinal obstruction especially in patients with ileostomy or colostomy. If obstruction is suspected, discontinue CUVPOSA™.

Avoid patient exposure to high ambient temperatures.  Heat prostration (fever and heat stroke due to decreased sweating) can occur with use of anticholinergic drugs such as CUVPOSA™.

Patients should not engage in age-appropriate activities requiring mental alertness such as operating a motor vehicle or other machinery or perform hazardous work, as CUVPOSA™ may cause drowsiness or blurred vision.

Use CUVPOSA™ with caution in patients with conditions that are exacerbated by anticholinergic drug effects including:

  • Autonomic neuropathy, renal disease and ulcerative colitis. (Large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason, may precipitate or aggravate "toxic megacolon," a serious complication of the disease.)
  • Hyperthyroidism, coronary heart disease, congestive heart failure, cardiac tachyarrhythmias, tachycardia, hypertension, and hiatal hernia associated with reflux esophagitis.

Glycopyrrolate reduces GI transit time which may result in altered release of certain drugs when formulated in delayed or controlled-release forms. CUVPOSA™ can increase serum levels of atenolol, metformin and digoxin (slow dissolution tablets; consider other dosage forms of digoxin). Dose reductions of atenolol or metformin may be needed.

CUVPOSA™ may decrease serum levels of haloperidol or levodopa. Consider dose i
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
2. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
3. Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
6. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
7. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
8. Mtech Announces Finalists for University of Maryland $75K Business Plan Competition
9. Caliper Life Sciences Announces Date and Location of its 2011 Annual Meeting of Stockholders
10. Kimberly-Clark Health Care Announces Strategic Green Partnerships, Commitment to Reducing Medical Waste
11. Dendreon Announces Presentation of Data at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 The ... for systemic delivery of therapeutic agents has been receiving ... drug delivery showing significant promise. The crucial formulation considerations ... delivery device play a major role in the efficiency ... in the development of new formulation techniques and devices ...
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
(Date:5/23/2013)... , May 24, 2013 3SBio Inc. ... "Company"), a leading China -based ... marketing biopharmaceutical products, announced today that, at an ... Company,s shareholders voted in favor of the proposal ... and plan of merger dated February 8, 2013, ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
(Date:5/24/2013)... have today released updated guidelines on Hormone Replacement Therapy ... the benefits and the risks. The new guidelines appear ... published by SAGE. , Over the last 11 ... of youth" to being considered extremely risky and only ... of the Women,s Health Initiative (WHI) trial in 2002, ...
(Date:5/24/2013)... May 24, 2013 Today marks the ... online Itinerary Builder. , The redesigned and enhanced ... unique vacation itineraries on their computer or mobile device ... The interactive tool allows users to fill in their ... through and select their choice of vacation packages, accommodations, ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 DiaperBuys.com is ... Baby Photo Contest. Lindsey Willis of Olathe, Kansas, won ... from DiaperBuys. Second prize was a three-month supply ... North Las Vegas, Nev.; and third prize, a one-month ... The contest was run through the company’s Facebook page. ...
(Date:5/24/2013)... 2013 Wednesday, 15th May 2013 | 10am ... to access webinar playback: http://bit.ly/10Rt0ZH , Ongoing regulatory ... markets. Across the globe and particularly in Europe, a number ... M&A activity . For dealmakers, understanding how the likes of ... Tax’ affects your corner of the market will give you ...
(Date:5/24/2013)... 24, 2013 http://www.resource4thepeople.com/defectivedrugs/Zithromax-lawsuits.html ... latest update involving allegations that the use of ... can allegedly cause potentially fatal irregular heart ... May 17, 2013* that Health Canada has joined ... that Zithromax can cause abnormal changes in the ...
Breaking Medicine News(10 mins):Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:DiaperBuys.com Announces Photo Contest Winners 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 3Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 2Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 3Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 4
... now choose a gender of their liking and some can ... procedure developed at the All India Institute of Medical Sciences ... already given proper gender identities as males or females and ... the premier research and referral institute said. ,"Treatment ...
... now looking at lactate with a much more positive ... brain in the immediate //hours after a traumatic brain ... are right, it could change how emergency room physicians ... in the first critical hours after injury. ...
... screen all 20,000-plus human genes for biological activity, scientists have ... cancer cells are to certain chemotherapy drugs.// ,In ... edition of the journal Nature, researchers at UT Southwestern Medical ... molecules – the first used by a university research center ...
... in full bloom, the American Academy of Otolaryngology – Head ... can do to cope with the pollen in the air, ... // ,This spring, pollen from blooming trees and plants ... causing itching eyes, sneezing, nasal stuffiness, nasal congestion and drainage, ...
... may result in erectile dysfunction, decreased libido, anemia, sarcopenia, ... ,While a low serum testosterone level is ... hypogonadism on overall physical functioning and fall risk has ... 23 issue of the Archives of Internal Medicine, Orwoll ...
... than one-third of Queensland men have never been screened for ... ,Screening for colorectal cancer currently has stronger scientific ... prostate or skin cancer, but a new study in the ... undergo the colorectal cancer test than the other two. ...
Cached Medicine News:Health News:New Procedure Paves Way for Eunuchs to Choose a Gender and Conceive 2Health News:Study Challenges Conventional Treatment of Traumatic Brain Injury 2Health News:Gene Screening Points Way to More Effective Chemotherapy 2Health News:April Showers Bring May Flowers – And Plenty of Pollen, To 2Health News:Low Serum Testosterone Levels Associated With Fall Risk in Elderly Men 2
... Rochester Medical's line of ... intermittent catheters you would ... four product configurations - ... antibacterial hydro - are ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
Medicine Products: